Top Markets
#1 PulseChain PulseChain +44.89%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +17.13%
#3 Ergo Ergo +16.71%
#4 RedStone RedStone +15.09%
#5 MarsCoin MarsCoin +13.98%
#6 SkyAI SkyAI +10.27%
#7 Lighter Lighter +9.20%
#8 Monad Monad +9.11%
#9 Solv Protocol xSolvBTC Solv Protocol xSolvBTC +8.41%
#10 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +8.24%
Coin of the day
PulseChain PulseChain
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Classifica tra le azioni #28046
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Prezzo delle azioni
$0.55
Ultima sincronizzazione: 2025-02-11
Capitalizzazione di mercato
$28.90M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Marinus Pharmaceuticals, Inc. (MRNS)

Categoria

Healthcare
Storico del prezzo dell'azione per Marinus Pharmaceuticals, Inc. (MRNS)
Prezzo di chiusura più alto: $0.55 il 2025-02-01

Prezzo di chiusura più basso: $8.00 il 2014-07-01
Storico del prezzo dell'azione di Marinus Pharmaceuticals, Inc. dal 2014 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2025 81.15%
2024 -86.72%
2023 124.80%
2022 -63.10%
2021 -18.02%
2020 95.30%
2019 -53.99%
2018 -51.67%
2017 728.84%
2016 -86.53%
2015 -16.46%
2014 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $552.07 39.99%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $168.77 527.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 56.22%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.82 -14.23%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $753.28 5.84%
CH